TITLE

Tamoxifen, raloxifene, and tibolone prevent primary invasive breast cancer but increase risk for adverse outcomes

AUTHOR(S)
Melnikow, Joy
PUB. DATE
March 2010
SOURCE
ACP Journal Club;3/16/2010, Vol. 152 Issue 3, p3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on a study related to the effectiveness of tamoxifen, raloxifene, and tibolone in reducing the risk of breast cancer in women without preexisting breast cancer. Study compared tamoxifen, raloxifene, or tibolone with placebo in the prevention of breast cancer. It concludes that in women without preexisting breast cancer, all three drugs can prevent invasive breast cancer and reduce risk for fractures but increase risk for thromboembolic events, stroke and endometrial cancer.
ACCESSION #
48839865

 

Related Articles

  • Breast cancer prevention study seeks participants.  // New York Amsterdam News;11/6/2003, Vol. 94 Issue 45, p26 

    The Comprehensive Cancer Center at Our Lady of Mercy Medical Center in the Bronx, New York is providing free breast-cancer risk assessments and seeks to enroll high-risk women in a national study on tamoxifen and raloxifene for the prevention of breast cancer. Sponsored by the National Cancer...

  • Selective Estrogen Receptor Modulators and Prevention of Invasive Breast Cancer. Gradishar, William J.; Cella, David // JAMA: Journal of the American Medical Association;6/21/2006, Vol. 295 Issue 23, p2784 

    The editorial focuses breast cancer research and chemoprevention with selective estrogen receptor modulators (SERMs). Tamoxifen has been shown to produce antitumor activity in patients with advanced breast cancer and the National Surgical Adjuvant Breast and Bowel Project (NSABP) indicates it...

  • Tamoxifen/Reloxifene Study Can Be Completed With Fewer Participants. Wang, Linda // JNCI: Journal of the National Cancer Institute;12/3/2003, Vol. 95 Issue 23, p1743 

    Reports on the conclusion made by the National Surgical Adjuvant Breast and Bowel Project that the Study of Tamoxifen and Raloxifene (STAR) can be completed with 3,000 postmenopausal women volunteers than it originally estimated. Design of STAR to compare whether the drug raloxifene can prevent...

  • STAR Trial Enrollment Ends Ahead of Schedule. Zielinski, Sarah L. // JNCI: Journal of the National Cancer Institute;9/1/2004, Vol. 96 Issue 17, p1275 

    Reports that the Study of Tamoxifen and Raloxifene, a clinical trial of breast cancer prevention in North America, has reached its enrollment goal in June 2004. Enrollment of postmenopausal women.

  • Primary chemoprevention of breast cancer: Are the adverse effects too burdensome? Prasad, Vinay; Diener-West, Marie // CMAJ: Canadian Medical Association Journal;6/16/2015, Vol. 187 Issue 9, pE276 

    The article comments on the renewed interest in the use of medication for the primary chemoprevention of breast cancer. Topics discussed include clinical trials which confirmed the role of raloxifene, tamoxifen and other selective estrogen-receptor modulators in reducing breast cancer risk, the...

  • Breast cancer prevention trials `can re-start'. Gavaghan, Helen // Nature;6/16/1994, Vol. 369 Issue 6481, p515 

    Reports on the recommendation by the Food and Drug Administration oncology advisory committee that the clinical trial of the breast cancer drug tamoxifen should be allowed to continue despite claims that it increases women's chances of developing endometrial cancer. National Cancer Institute's...

  • Our Lady of Mercy Comprehensive Cancer Center participates in the largest study ever conducted on breast-cancer prevention.  // New York Amsterdam News;3/20/2003, Vol. 94 Issue 12, p19 

    Reports on STAR, a study designed to compare the effectiveness of osteoporosis prevention and treatment drug raloxifene and tamoxifen in reducing breast cancer development in the U.S. Center conducting the study; Eligibility conditions for women to join the study.

  • Treatment - Prevention.  // Current Medical Literature: Breast Cancer;2010, Vol. 22 Issue 1, p35 

    The article discusses the effectiveness and safety of tamoxifen, raloxifene and tribolone in decreasing the threat of primary breast cancer among women by sub-group through age, family record of breast cancer and menopausal condition. It states that the study contains double-blind,...

  • Breast Cancer Prevented in Some Women with Drug Treatment. SHAUGHNESSY, ALLEN F. // American Family Physician;11/1/2013, Vol. 88 Issue 9, p608 

    The article discusses the study "Use of Medications to Reduce Risk for Primary Breast Cancer: A Systematic Review for the U.S. Preventive Services Task Force," conducted by H. D. Nelson and colleagues, published in a 2013 issue of "Annals of Internal Medicine" journal. It cites reduced cases of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics